XTX Topco Ltd Purchases New Stake in Altimmune, Inc. (NASDAQ:ALT)

XTX Topco Ltd acquired a new position in Altimmune, Inc. (NASDAQ:ALT) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 14,378 shares of the company’s stock, valued at approximately $96,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sectoral Asset Management Inc. purchased a new position in shares of Altimmune during the 4th quarter valued at $1,922,000. Lighthouse Investment Partners LLC bought a new position in Altimmune during the fourth quarter worth about $4,493,000. Pennant Investors LP purchased a new position in shares of Altimmune in the fourth quarter worth about $1,235,000. Gerber LLC bought a new stake in shares of Altimmune in the fourth quarter valued at approximately $2,878,000. Finally, Commonwealth Equity Services LLC raised its position in shares of Altimmune by 31.5% in the first quarter. Commonwealth Equity Services LLC now owns 79,945 shares of the company’s stock valued at $814,000 after purchasing an additional 19,172 shares during the period. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Altimmune

In other news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $6.90, for a total value of $110,475.90. Following the completion of the transaction, the director now directly owns 41,958 shares in the company, valued at approximately $289,510.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

ALT has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research note on Thursday, August 22nd. Evercore ISI raised Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler restated an “overweight” rating and issued a $25.00 target price on shares of Altimmune in a research note on Friday, June 21st. Finally, B. Riley reiterated a “buy” rating and set a $20.00 price target on shares of Altimmune in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Altimmune has an average rating of “Moderate Buy” and an average target price of $18.80.

Altimmune Stock Up 2.4 %

Altimmune stock opened at $6.29 on Wednesday. The stock has a market cap of $445.97 million, a price-to-earnings ratio of -3.96 and a beta of 0.08. The business has a 50-day simple moving average of $6.67 and a 200 day simple moving average of $7.20. Altimmune, Inc. has a 52 week low of $2.09 and a 52 week high of $14.84.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Altimmune had a negative net margin of 24,778.97% and a negative return on equity of 53.09%. The company had revenue of $0.01 million during the quarter. During the same quarter in the prior year, the company earned ($0.32) earnings per share. On average, research analysts anticipate that Altimmune, Inc. will post -0.54 earnings per share for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.